UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 11, 2015

AETHLON MEDICAL, INC.
(Exact name of registrant as specified in its charter)

Nevada	001-37487	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

9635 Granite Ridge Drive, Suite 100 San Diego, California (Address of principal executive offices)	92123 (Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward-looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, the registrant's operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the registrant believes that the expectations reflected in the forward-looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 7.01 REGULATION FD DISCLOSURE.

Today, November 11, 2015, Mr. James Joyce, Chief Executive Officer of Aethlon Medical, Inc. (the “Company”), presented at IN3 Medical Device 360° Summit Conference. A link to the presentation may be accessed on the Company’s website under the investor relations section of the website. The website address is www.aethlonmedical.com. No portion of the website shall be deemed to be incorporated into this Current Report on Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – IN3 Medical Device 360° Summit Conference – November 11, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

Dated: November 11, 2015

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – IN3 Medical Device 360° Summit Conference – November 11, 2015

Exhibit 99.1

Aethlon Medical, Inc.

Therapeutic Partnering Opportunities

IN3 Medical Device Summit

November 11, 2015

Jim Joyce
Chairman, CEO

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon ADAPT™ system, the Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

About Aethlon Medical

- Nasdaq: AEMD
- Headquartered in San Diego, California
- We Create Affinity Biofiltration Devices to Treat Life-Threatening Diseases

Aethlon Affinity Biofiltration Technology

- Expansive Therapeutic Device Platform
  - The Aethlon ADAPT™ System
    - Adaptive Dialysis-Like Affinity Platform Technology
    - Intersection of affinity compounds & advanced plasma membrane technologies
    - Rapid elimination of circulating disease targets
  - Lead product provides clinical pathway into infectious disease and oncology
    - Being advanced under an FDA approved clinical study

The Aethlon Hemopurifier®

Single-Use Clearance of Viruses & Tumor-Secreted Exosomes

aethlon MEDICAL, INC.

DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES

aethlon MEDICAL, INC.

Unmet Needs in Infectious Disease

- Antiviral Drug-Resistance
- Untreatable Latent Viruses
  - Organ Transplant
  - Sepsis
    - DARPA DLT Program
- Bioterror & Pandemic Threats
  - Leading broad-spectrum countermeasure


TIME
DEC. 1 / DEC. 8, 2014
THE 25 BEST INVENTIONS OF 2014
aethlon
MEDICAL, INC.


TIME
aethlon
MEDICAL, INC.


Ebola
Dengue
Pandemic Influenza
BIOTERROR & PANDEMIC VALIDATIONS
Lassa
West Nile
Pox Viruses
aethlon MEDICAL, INC.

Human Treatment Experience



HIV, Hepatitis-C and Ebola Virus

aethlon MEDICAL, INC.


A Case Study of Hemopurifier® Therapy
Against an Untreatable Viral Pathogen
aethlon
MEDICAL, INC.

The Treatment of Ebola Virus
Frankfurt University Hospital

Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)

aethlon MEDICAL, INC.

Hemopurifier® therapy administration to a comatose Ebola patient with multiple-organ failure

aethlon MEDICAL, INC.

Dr. Stefan Büttner
Holding Hemopurifier®
After Ebola Treatment

aethlon MEDICAL, INC.

Ebola Treatment Data

Presented By Dr. Helmut Geiger

American Society of Nephrology Annual Meeting

- 6.5 hour Hemopurifier® therapy administration
- Pre-treatment viral load: 400,000 copies/ml
- Post-treatment viral load: 1,000 copies/ml
- 242 million of Ebola viruses captured
- Patient recovered and returned home

SAVE LIVES

Application of the Hemopurifier® in Cancer

aethlon MEDICAL, INC.

Hemopurifier® Capture of Tumor-Secreted Exosomes



aethlon MEDICAL, INC.

Tumor-Secreted Exosomes
A Significant Unmet Medical Need in Cancer

- Trigger apoptosis of immune cells
- Contribute to drug and chemotherapy resistance
- Promote angiogenesis
- Seed the creation and spread of metastasis
- Exosome load correlates with stage of cancer


AS WE CLINICALLY PROGRESS OUR HEMOPURIFIER®,
WE WILL PARTNER TO ESTABLISH A PIPELINE OF
ADAPT™ BASED THERAPIES
aethlon
MEDICAL, INC.

Disease Partnering Characteristics

- Must be a life-threatening disease
- Limited or no proven therapeutic options
- Indications affecting < 4000 per year may be given humanitarian/orphan consideration
- Disease promoting factors must be accessible in the circulatory system
  - Single or multi-target (cocktail) mechanism
    - Example: Removal of tumor-secreted exosomes + other oncology targets

Partnering Candidate Profile

- Industry, VC and Institutional Healthcare Investors
- Academic research teams
- Therapeutic organizations interested in testing a device pathway for their affinity compounds

CONTACT:

Aethlon Medical, Inc
9635 Granite Ridge Drive
Suite 100
San Diego, California 92123

Jim Joyce
Chairman & CEO
jj@aethlonmedical.com
858.459.7800 x301